Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure

Best Practice and Research: Clinical Rheumatology

Volumn 26, Issue 4, 2012, Pages 489-503

  Bernstein, Elana J ^a   Schmidt Lauber, Christian ^b   Kay, Jonathan ^c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Chronic kidney disease; Gadolinium; GBCA; Haemodialysis; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Peritoneal dialysis; Renal transplantation

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOXETIC ACID; HEMOGLOBIN A1C; HISTAMINE H2 RECEPTOR ANTAGONIST; IMATINIB; RAPAMYCIN; SODIUM THIOSULFATE; THALIDOMIDE; UROPORPHYRIN; UROPORPHYRINOGEN;

ACUTE KIDNEY FAILURE; AMYLOIDOSIS; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC KIDNEY DISEASE; DIFFERENTIAL DIAGNOSIS; DUPUYTREN CONTRACTURE; ELECTROMYOGRAPHY; ELECTRON MICROSCOPY; EOSINOPHIL COUNT; EOSINOPHILIC FASCIITIS; ERYTHEMA; HAIR LOSS; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; JOINT CONTRACTURE; KIDNEY GRAFT; LICHEN SCLEROSUS ET ATROPHICUS; LIPODERMATOSCLEROSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; SCLERODERMA; SCLEROMYXEDEMA; SKIN BIOPSY; SKINFOLD; ULTRAVIOLET A RADIATION;

EID: 84867385398     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2012.07.008     Document Type: Review

References (95)

1. Fibrosing skin condition among patients with renal disease-United States and Europe, 1997-2002 MMWR Morbidity and Mortality Weekly Report 51 2002 25 26
2. S.E. Cowper, H.S. Robin, S.M. Steinberg, L.D. Su, S. Gupta, and P.E. LeBoit Scleromyxoedema-like cutaneous diseases in renal-dialysis patients Lancet 356 2000 1000 1001
3. S.E. Cowper, L.D. Su, J. Bhawan, H.S. Robin, and P.E. LeBoit Nephrogenic fibrosing dermopathy American Journal of Dermatopathology 23 2001 383 393
4. S.R. Daram, C.M. Cortese, and B. Bastani Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 46 2005 754 759
5. M. Girardi, J. Kay, D.M. Elston, P.E. Leboit, A. Abu-Alfa, and S.E. Cowper Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations Journal of the American Academy of Dermatology 65 2011 19
6. N. Bangsgaard, P. Marckmann, K. Rossen, and L. Skov Nephrogenic systemic fibrosis: late skin manifestations Archives of Dermatology 145 2009 183 187
7. S.L. Moschella, J. Kay, B.T. Mackool, and V. Liu Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin The New England Journal of Medicine 351 2004 2219 2227
8. S.A. Jimenez, C.M. Artlett, N. Sandorfi, C. Derk, K. Latinis, and H. Sawaya Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin Arthritis and Rheumatism 50 2004 2660 2666
9. J. Kay, H. Bazari, L.L. Avery, and A.F. Koreishi Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin The New England Journal of Medicine 358 2008 827 838
10. A.F. Koreishi, R.M. Nazarian, A.J. Saenz, V.E. Klepeis, A.G. McDonald, and A.B. Farris Nephrogenic systemic fibrosis: a pathologic study of autopsy cases Arch Pathol Lab Med 133 2009 1943 1948
11. F.A. Mendoza, C.M. Artlett, N. Sandorfi, K. Latinis, S. Piera-Velazquez, and S.A. Jimenez Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature Seminars in Arthritis and Rheumatism 35 2006 238 249
12. S. Sanyal, P. Marckmann, S. Scherer, and J.L. Abraham Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis-an autopsy-based review Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 26 2011 3616 3626
13. A. Barker-Griffith, J. Goldberg, and J.L. Abraham Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis Arch Ophthalmol 129 2011 661 663
14. T. Grobner Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 21 2006 1104 1108
15. D.J. Todd, A. Kagan, L.B. Chibnik, and J. Kay Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure Arthritis and Rheumatism 56 2007 3433 3441
16. A. Deo, M. Fogel, and S.E. Cowper Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure Clinical Journal of the American Society of Nephrology: CJASN 2 2007 264 267
17. J.B. Othersen, J.C. Maize, R.F. Woolson, and M.N. Budisavljevic Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 22 2007 3179 3185
18. P. Marckmann, L. Skov, K. Rossen, A. Dupont, M.B. Damholt, and J.G. Heaf Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging Journal of the American Society of Nephrology: JASN 17 2006 2359 2362
19. A. Khurana, V.M. Runge, M. Narayanan, J.F. Greene Jr., and A.E. Nickel Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan) Investigative Radiology 42 2007 139 145
20. E.A. Sadowski, L.K. Bennett, M.R. Chan, A.L. Wentland, A.L. Garrett, and R.W. Garrett Nephrogenic systemic fibrosis: risk factors and incidence estimation Radiology 243 2007 148 157
21. J.A. Moreno-Romero, S. Segura, J.M. Mascaro Jr., S.E. Cowper, M. Julia, and E. Poch Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor The British Journal of Dermatology 157 2007 783 787
22. H.H. Abujudeh, R. Kaewlai, A. Kagan, L.B. Chibnik, R.M. Nazarian, and W.A. High Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients Radiology 253 2009 81 89
23. A.B. Hill The environment and disease: association or causation? Proc R Soc Med 58 1965 295 300
24. J. Kay, and L. Czirjak Gadolinium and systemic fibrosis: guilt by association Annals of the Rheumatic Diseases 69 2010 1895 1897
25. D.R. Broome, M.S. Girguis, P.W. Baron, A.C. Cottrell, I. Kjellin, and G.A. Kirk Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned AJR Americam Journal of Roentgenology 188 2007 586 592
26. T.A. Collidge, P.C. Thomson, P.B. Mark, J.P. Traynor, A.G. Jardine, and S.T. Morris Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort Radiology 245 2007 168 175
27. C. Rydahl, H.S. Thomsen, and P. Marckmann High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent Investigative Radiology 43 2008 141 144
28. M.D. Bridges, B.S. St Amant, R.B. McNeil, J.G. Cernigliaro, J.P. Dwyer, and P.M. Fitzpatrick High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function AJR American Journal of Roentgenology 192 2009 1538 1543
29. M.R. Prince, H. Zhang, M. Morris, J.L. MacGregor, M.E. Grossman, and J. Silberzweig Incidence of nephrogenic systemic fibrosis at two large medical centers Radiology 248 2008 807 816
30. T.B. Cassis, J.M. Jackson, G.B. Sonnier, and J.P. Callen Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis International Journal of Dermatology 45 2006 56 59
31. R.M. Nazarian, R.V. Mandal, A. Kagan, J. Kay, and L.M. Duncan Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid Journal of the American Academy of Dermatology 64 2011 741 747
32. S.E. Cowper, and R. Bucala Nephrogenic fibrosing dermopathy: suspect identified, motive unclear American Journal of Dermatopathology 25 2003 358
33. J. Kay Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction Annals of the Rheumatic Diseases 67 Suppl. 3 2008 iii66 iii69
34. W.A. High, R.A. Ayers, J. Chandler, G. Zito, and S.E. Cowper Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis Journal of the American Academy of Dermatology 56 2007 21 26
35. A.S. Boyd, J.A. Zic, and J.L. Abraham Gadolinium deposition in nephrogenic fibrosing dermopathy Journal of the American Academy of Dermatology 56 2007 27 30
36. W.A. High, R.A. Ayers, and S.E. Cowper Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis Journal of the American Academy of Dermatology 56 2007 710 712
37. A.S. Boyd, S. Sanyal, and J.L. Abraham Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents Journal of the American Academy of Dermatology 59 2008 356 358
38. T. Frenzel, P. Lengsfeld, H. Schirmer, J. Hutter, and H.J. Weinmann Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C Investigative Radiology 43 2008 817 828
39. A.K. Haemel, E.A. Sadowski, M.M. Shafer, and A. Djamali Update on nephrogenic systemic fibrosis: are we making progress? International Journal of Dermatology 50 2011 659 666
40. Y. Tsushima, E. Kanal, and H.S. Thomsen Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases The British Journal of Radiology 83 2010 590 595
41. P.J. Wermuth, and S.A. Jimenez Gadolinium compounds signaling through TLR 4 and TLR 7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis Journal of Immunology 189 2012 318 327
42. F. Del Galdo, P.J. Wermuth, S. Addya, P. Fortina, and S.A. Jimenez NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis Annals of the Rheumatic Diseases 69 2010 2024 2033
43. T. Steger-Hartmann, M. Raschke, B. Riefke, H. Pietsch, M.A. Sieber, and J. Walter The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft Fur Toxikologische Pathologie 61 2009 537 552
44. J.P. Mizgerd, R.M. Molina, R.C. Stearns, J.D. Brain, and A.E. Warner Gadolinium induces macrophage apoptosis Journal of Leukocyte Biology 59 1996 189 195
45. P.J. Wermuth, F. Del Galdo, and S.A. Jimenez Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents Arthritis and Rheumatism 60 2009 1508 1518
46. S. Piera-Velazquez, N. Louneva, J. Fertala, P.J. Wermuth, F. Del Galdo, and S.A. Jimenez Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis Annals of the Rheumatic Diseases 69 2010 2017 2023
47. J.H. Distler, A. Jungel, L.C. Huber, U. Schulze-Horsel, J. Zwerina, and R.E. Gay Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis and Rheumatism 56 2007 311 322
48. S. Chandran, J. Petersen, C. Jacobs, D. Fiorentino, K. Doeden, and R.A. Lafayette Imatinib in the treatment of nephrogenic systemic fibrosis American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 53 2009 129 132
49. J. Kay, and W.A. High Imatinib mesylate treatment of nephrogenic systemic fibrosis Arthritis and Rheumatism 58 2008 2543 2548
50. M.A. Sieber, P. Lengsfeld, T. Frenzel, S. Golfier, H. Schmitt-Willich, and F. Siegmund Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions European Radiology 18 2008 2164 2173
51. H. Pietsch, P. Lengsfeld, T. Steger-Hartmann, A. Lowe, T. Frenzel, and J. Hutter Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents Investigative Radiology 44 2009 226 233
52. P. Joffe, H.S. Thomsen, and M. Meusel Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis Academic Radiology 5 1998 491 502
53. T.A. Hope, W.A. High, P.E. Leboit, B. Chaopathomkul, V.S. Rogut, and R.J. Herfkens Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron Radiology 253 2009 390 398
54. R.D. Swartz, L.J. Crofford, S.H. Phan, R.W. Ike, and L.D. Su Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure American Journal of Medicine 114 2003 563 572
55. N.B. Aires, M.N. Sotto, and M.M. Nico Nephrogenic fibrosing dermopathy: report of two cases Acta Dermato-venereologica 87 2007 521 524
56. P.W. Baron, K. Cantos, D.J. Hillebrand, K.Q. Hu, O.N. Ojogho, and S. Nehlsen-Cannarella Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis American Journal of Dermatopathology 25 2003 204 209
57. G. Tsagalis, E. Psimenou, and A. Laggouranis Combination treatment with plasmapheresis and sirolimus does not seem to benefit nephrogenic systemic fibrosis The International Journal of Artificial Organs 31 2008 913 914
58. M. Gilliet, A. Cozzio, G. Burg, and F.O. Nestle Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis The British Journal of Dermatology 152 2005 531 536
59. S. Lauchli, C. Zortea-Caflisch, F.O. Nestle, G. Burg, and W. Kempf Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis Dermatology 208 2004 278 280
60. K. Mathur, S. Morris, C. Deighan, R. Green, and K.W. Douglas Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: three case reports and review of literature Journal of Clinical Apheresis 23 2008 144 150
61. H. Richmond, J. Zwerner, Y. Kim, and D. Fiorentino Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis Archives of Dermatology 143 2007 1025 1030
62. I.M. Wahba, K. White, M. Meyer, and E.L. Simpson The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy-report of two cases and review of the literature Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 22 2007 631 636
63. K.L. Duffy, L. Green, R. Harris, and D. Powell Treatment of nephrogenic systemic fibrosis with Re-PUVA Journal of the American Academy of Dermatology 59 2008 S39 S40
64. R. Kafi, G.J. Fisher, T. Quan, Y. Shao, R. Wang, and J.J. Voorhees UV-A1 phototherapy improves nephrogenic fibrosing dermopathy Archives of Dermatology 140 2004 1322 1324
65. A. Kreuter, T. Gambichler, S.M. Weiner, and G. Schieren Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis Archives of Dermatology 144 2008 1527 1529
66. K.T. Tran, H.B. Prather, C.J. Cockerell, and H. Jacobe UV-A1 therapy for nephrogenic systemic fibrosis Archives of Dermatology 145 2009 1170 1174
67. S. Swaminathan, J.L. Arbiser, K.M. Hiatt, W. High, S. Abul-Ezz, and T.D. Horn Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase Journal of the American Academy of Dermatology 62 2010 343 345
68. D. Kadiyala, D.A. Roer, and M.A. Perazella Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 53 2009 133 137
69. P. Marckmann, A.H. Nielsen, and J.J. Sloth Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 23 2008 3280 3282
70. P. Yerram, G. Saab, P.R. Karuparthi, M.R. Hayden, and R. Khanna Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate Clinical Journal of the American Society of Nephrology: CJASN 2 2007 258 263
71. M.C. Cuffy, M. Singh, R. Formica, E. Simmons, A.K. Abu Alfa, and K. Carlson Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 26 2011 1099 1101
72. F. Jan, J.M. Segal, J. Dyer, P. LeBoit, E. Siegfried, and I.J. Frieden Nephrogenic fibrosing dermopathy: two pediatric cases J Pediatr 143 2003 678 681
73. N. Leung, A. Shaikh, F.G. Cosio, M.D. Griffin, S.C. Textor, and J.M. Gloor The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 10 2010 558 562
74. M. Panesar, S. Banerjee, and G.W. Barone Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation Clinical Transplantation 22 2008 803 808
75. Y. Wang, T.K. Alkasab, O. Narin, R.M. Nazarian, R. Kaewlai, and J. Kay Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines Radiology 260 2011 105 111
76. A.N. Mayeno, and G.J. Gleich Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale Trends in Biotechnology 12 1994 346 352
77. F.J. Martinez-Tello, J.J. Navas-Palacios, J.R. Ricoy, R. Gil-Martin, J.M. Conde-Zurita, and F. Colina-Ruiz Delgado Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain Virchows Archiv A, Pathological Anatomy and Histology 397 1982 261 285
78. T.C. Lauenstein, K. Salman, R. Morreira, S. Tata, D. Tudorascu, and G. Baramidze Nephrogenic systemic fibrosis: center case review Journal of Magnetic Resonance Imaging: JMRI 26 2007 1198 1203
79. W. Chen, S.L. Huang, C.S. Huang, M.C. Tsai, H.M. Lai, and C.C. Lui Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan European Journal of Dermatology: EJD 19 2009 44 49
80. C. Chrysochou, D.L. Buckley, P. Dark, A. Cowie, and P.A. Kalra Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience Journal of Magnetic Resonance Imaging: JMRI 29 2009 887 894
81. G. Heinz-Peer, A. Neruda, B. Watschinger, A. Vychytil, A. Geusau, and M. Haumer Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease European Journal of Radiology 76 2010 129 134
82. T.A. Hope, R.J. Herfkens, K.S. Denianke, P.E. LeBoit, Y.Y. Hung, and E. Weil Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine Investigative Radiology 44 2009 135 139
83. C.U. Lee, C.M. Wood, G.K. Hesley, N. Leung, M.D. Bridges, and J.T. Lund Large sample of nephrogenic systemic fibrosis cases from a single institution Archives of Dermatology 145 2009 1095 1102
84. N. Janus, V. Launay-Vacher, S. Karie, O. Clement, E. Ledneva, and C. Frances Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study European Journal of Radiology 73 2010 357 359
85. A.A. Lemy, V. del Marmol, A. Kolivras, W.A. High, C. Matos, and M. Laporte Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience Journal of the American Academy of Dermatology 63 2010 389 399
86. D.R. Martin, S.K. Krishnamoorthy, B. Kalb, K.N. Salman, P. Sharma, and J.D. Carew Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols Journal of Magnetic Resonance Imaging: JMRI 31 2010 440 446
87. D.S. Chow, S. Bahrami, S.S. Raman, S. Rotchel, J.W. Sayre, and R.W. Busuttil Risk of nephrogenic systemic fibrosis in liver transplantation patients AJR American Journal of Roentgenology 197 2011 658 662
88. J.C. Kendrick-Jones, D.M. Voss, and J.R. De Zoysa Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006 Nephrology (Carlton) 16 2011 243 248
89. A. Alhadad, G. Sterner, A. Svensson, H. Alhadad, and P. Leander Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden Scandinavian Journal of Urology and Nephrology 46 2012 48 53
90. N.S. Anavekar, A.H. Chong, R. Norris, J. Dowling, and D. Goodman Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient Australasian Journal of Dermatology 49 2008 44 47
91. I.M. Wahba, E.L. Simpson, and K. White Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 7 2007 2425 2432
92. A.S. Weiss, M.S. Lucia, and I. Teitelbaum A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis Nature Clinical Practice Nephrology 3 2007 111 115
93. EMA Assessment report for gadolinium-containing contrast agents (Procedure No. EMEA/H/A-31/1097) 2010 European Medicines Agency London [accessed August 1, 2011]; Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Referrals-document/gadolinium-31/WC500099538.pdf
94. J.M. Idee, M. Port, C. Medina, E. Lancelot, E. Fayoux, and S. Ballet Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review Toxicology 248 2008 77 88
95. J.M. Idee, M. Port, I. Raynal, M. Schaefer, S. Le Greneur, and C. Corot Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review Fundamental & Clinical Pharmacology 20 2006 563 576